As of Aug 21
| +0.49 / +0.68%|
The 21 analysts offering 12-month price forecasts for Gilead Sciences have a median target of 82.00, with a high estimate of 90.00 and a low estimate of 73.00. The median estimate represents a +12.95% increase from the last price of 72.60.
The current consensus among 26 polled investment analysts is to Hold stock in Gilead Sciences. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.